Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Webnewswire
News for the people
Downtown
Magazine PRO
12.6
C
London
Thursday, May 1, 2025
Home
Refund Policy
Privacy Policy
Terms & Conditions
Submit Your Press Releases (Free)
Sponsored Posts
About
Facebook
Instagram
Twitter
Youtube
Webnewswire
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
Webnewswire
News for the people
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Search
Subscribe
Home
Tags
SinoMab
Tag: SinoMab
Business
Japan – SinoMab BioScience Limited Breakthrough Phase 1b POC Results for SM17 in Atopic Dermatitis
Editor
-
April 10, 2025
0
Business
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy
-
April 17, 2024
0
Business
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP
Editor
-
August 15, 2023
0
Business
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE
Editor
-
June 13, 2023
0
Business
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE
-
May 22, 2023
0
Business
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company
-
November 5, 2022
0
Business
SinoMab Received the Highest Subsidy from HKSTP
-
July 9, 2022
0
Business
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
-
June 17, 2022
0
Business
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
-
June 9, 2022
0
Business
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
-
February 8, 2022
0
Business
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
-
November 30, 2021
0
Uncategorized
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
-
September 17, 2021
0
